14Jul
Japan Tightens Foreign Direct Investment Regulations on Life Science Companies - Prior notification requirements under the Japanese regulations were expanded to cover investments in life science companies.
On June 15, 2020, the Japanese government implemented new regulations that designate the manufacture of pharmaceuticals for infectious diseases and the manufacture of highly-controlled medical devices (medical devices that are classified as Class III or Class IV in Japan, such as a heart–lung machines and ventilators) as both "Designated Businesses" and "Core Businesses" under the Foreign Exchange and Foreign Trade Act of Japan ("FEFTA"). The new regulations were adopted in light of the COVID-19...
By:
Jones Day
Related
On December 19, 2019, the U.S. General Services Administration (“GSA”) issued a final rule which a...
Read More >
On Monday, August 17, 2020, Baker Donelson's Clinton Sanko sat down with Wendell Jisa, CEO of Reveal...
Read More >
In Borealis Power Holdings Inc. v. Hunt Strategic Utility Investment, L.L.C., the Delaware Supreme C...
Read More >
Join us for an in-depth conversation with top attorneys from Duane Morris LLP, Fenton Grant Mayfield...
Read More >
A properly implemented employment arbitration program can provide a variety of benefits to employers...
Read More >
In the world of M&A and private equity deals, buyer-side representation and warranties insurance (RW...
Read More >